Annual report pursuant to Section 13 and 15(d)

Licenses Acquired (Tables)

v3.21.1
Licenses Acquired (Tables)
12 Months Ended
Dec. 31, 2020
Licenses Acquired  
Schedule of Research and Development-Licenses

For the years ended December 31, 2020 and 2019, the Company’s research and development-licenses acquired are comprised of the following:

For the Year Ended

December 31, 

($ in thousands)

    

2020

    

2019

Partner companies:

 

  

 

  

Avenue

$

$

1,000

Aevitas

62

Baergic

 

11

 

3,290

Cellvation

 

1

 

Helocyte

450

Mustang

2,489

1,350

Oncogenuity

271

Total

$

2,834

$

6,090

Schedule of Research and Development for Licenses Acquired

For the years ended December 31, 2020 and 2019 Mustang recorded the following expense in research and development – licenses acquired:

For the Year Ended December 31, 

($ in thousands)

    

2020

    

2019

City of Hope National Medical Center

CD123 (MB-102)3

$

334

$

250

IL13Rα2 (MB-101) 3

334

HER2 (MB-103)1

500

CS1 (MB-104)

200

200

PSCA (MB-105)3

 

200

 

200

Spacer

334

Fred Hutch - CD20 (MB-106)2

300

Nationwide Children’s Hospital - C134 (MB-108)

200

CSL Behring (Calimmune)

170

200

UCLA

300

SIRION LentiBOOSTTM

117

Total

$

2,489

$

1,350